HIV Cure Strategies: How Good Must They Be to Improve on Current Antiretroviral Therapy?

Paul E Sax, Alexis Sypek, Bethany K Berkowitz, Bethany L Morris, Elena Losina, A David Paltiel, Kathleen A Kelly, George R Seage, Rochelle P Walensky, Milton C Weinstein, Joseph Eron and Kenneth A Freedberg

PLOS ONE, 2014, vol. 9, issue 11, 1-8

Abstract: Background: We examined efficacy, toxicity, relapse, cost, and quality-of-life thresholds of hypothetical HIV cure interventions that would make them cost-effective compared to life-long antiretroviral therapy (ART). Methods: We used a computer simulation model to assess three HIV cure strategies: Gene Therapy, Chemotherapy, and Stem Cell Transplantation (SCT), each compared to ART. Efficacy and cost parameters were varied widely in sensitivity analysis. Outcomes included quality-adjusted life expectancy, lifetime cost, and cost-effectiveness in dollars/quality-adjusted life year ($/QALY) gained. Strategies were deemed cost-effective with incremental cost-effectiveness ratios

Date: 2014
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0113031 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 13031&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0113031

DOI: 10.1371/journal.pone.0113031

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().